Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) in... von Chuan Tang, Seng, Nguyen, Luan N., Sparidans, Rolf W., Wagenaar, Els, Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) von Kort, Anita, Sparidans, Rolf W., Wagenaar, Els, Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) von Kort, Anita, Durmus, Selvi, Sparidans, Rolf W., Wagenaar, Els, Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation von van Hoppe, Stéphanie, Sparidans, Rolf W., Wagenaar, Els, Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699) von Durmus, Selvi, Sparidans, Rolf W., van Esch, Anita, Wagenaar, Els, Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) von van Hoppe, Stéphanie, Jamalpoor, Amer, Rood, Johannes J.M., Wagenaar, Els, Sparidans, Rolf W., Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites von Retmana, Irene A., Beijnen, Jos H., Sparidans, Rolf W.

Volltext

Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry von van den Broek, Irene, Sparidans, Rolf W., Schellens, Jan H.M., Beijnen, Jos H.

Volltext

OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation von Wang, Yaogeng, Sparidans, Rolf W., Li, Wenlong, Lebre, Maria C., Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease von Koelink, Pim J, Overbeek, Saskia A, Braber, Saskia, Morgan, Mary E, Henricks, Paul A J, Roda, Mojtaba Abdul, Verspaget, Hein W, Wolfkamp, Simone C, te Velde, Anje A, Jones, Caleb W, Jackson, Patricia L, Blalock, J Edwin, Sparidans, Rolf W, Kruijtzer, John A W, Garssen, Johan, Folkerts, Gert, Kraneveld, Aletta D

Volltext

P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability von Li, Wenlong, Sparidans, Rolf W., Wang, Yaogeng, Lebre, Maria C., Beijnen, Jos H., Schinkel, Alfred H.

Volltext

ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib von Wang, Yaogeng, Sparidans, Rolf W., Potters, Sander, Lebre, Maria C., Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells von Gholizadeh, Shima, Dolman, Emmy M., Wieriks, Rebecca, Sparidans, Rolf W., Hennink, Wim E., Kok, Robbert J.

Volltext

The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib von Loos, Nancy H.C., Sparidans, Rolf W., Heydari, Paniz, Bui, Viët, Lebre, Maria C., Beijnen, Jos H., Schinkel, Alfred H.

Volltext

P‐glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450‐3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib von Li, Wenlong, Sparidans, Rolf W., Wang, Yaogeng, Lebre, Maria C., Wagenaar, Els, Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma von Rood, Johannes J.M., van Bussel, Mark T.J., Schellens, Jan H.M., Beijnen, Jos H., Sparidans, Rolf W.

Volltext

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation von Lagas, Jurjen S, van Waterschoot, Robert A B, Sparidans, Rolf W, Wagenaar, Els, Beijnen, Jos H, Schinkel, Alfred H

Volltext

Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse stu... von Retmana, Irene A., Çelebi, Nefise, Rijmers, Jamie, Schinkel, Alfred H., Beijnen, Jos H., Sparidans, Rolf W.

Volltext

Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs von Li, Wenlong, Iusuf, Dilek, Sparidans, Rolf W., Wagenaar, Els, Wang, Yaogeng, de Waart, Dirk R., Martins, Margarida L.F., van Hoppe, Stéphanie, Lebre, Maria C., van Tellingen, Olaf, Beijnen, Jos H., Schinkel, Alfred H.

Volltext

Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue hom... von Sparidans, Rolf W., Li, Wenlong, Schinkel, Alfred H., Schellens, Jan H.M., Beijnen, Jos H.

Volltext